N eurological and psychiatric diseases together affect over 35% of the adult population [1] [2] [3] and often involve the dysfunction of neural circuits defined by specific spatial locations and cell types [4] [5] [6] [7] [8] . However, conventional pharmacological treatments for such diseases act throughout the brain, leading to significant side effects. While invasive surgery is able to target specific parts of the brain for excision or electrical stimulation, it carries significant risks. Emerging therapies based on gene or cellular therapy are also typically delivered using surgical injections, often with limited spatial coverage and acting in an always-on fashion lacking temporal dose control. Here, we introduce an alternative approach to neuromodulation that delivers spatial, cell-type and temporal control without surgery. This approach-which we call acoustically targeted chemogenetics (ATAC)-achieves this performance by combining three recently developed technologies: focused ultrasound bloodbrain barrier opening (FUS-BBBO) for spatial targeting, adenoassociated virus (AAV) vectors for delivery of genes to specific cell types, and engineered chemogenetic receptors for modulation of targeted neurons using orally bioavailable 9 compounds (Fig. 1a) . FUS is an established biomedical technology that takes advantage of ultrasound's ability to focus in deep tissues such as the brain with millimetre spatial precision [10] [11] [12] . FUS-BBBO combines transcranial ultrasound in the low-intensity regime with systemically administered microbubbles, whose stable cavitation in blood vessels at the ultrasound focus results in localized, temporary and reversible opening of the BBB 13, 14 . This allows small molecules, proteins, nanoparticles or viral capsids 13, [15] [16] [17] [18] [19] [20] [21] to enter the brain at the site of the applied ultrasound. FUS-BBBO has been used in multiple animal species 13, 22, 23 and is undergoing clinical testing
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In the ATAC paradigm, a one-time FUS-BBBO procedure 'paints' the region or regions of the brain to be modulated, while AAV vectors and DREADDs sensitize specific neurons in these regions to subsequent excitation or inhibition through administration of clozapine-N-oxide (CNO) (Fig. 1b) . While the three components underlying this paradigm have been separately established, and previous work has combined AAVs with either BBBO or DREADDs, we report the integration of these three technologies to achieve ATAC's unique combination of spatial, cell-type and temporal control of neural circuits. Furthermore, we demonstrate the use of FUS-BBBO to deliver genes affecting behaviour through neuromodulation and provide fully non-invasive control of behaviour via genetically targeted neuromodulation in wild-type animals.
Here, we demonstrate the basic capabilities of ATAC in mice by evaluating the ability of this technique to selectively activate or inhibit excitatory neurons in the hippocampus and midbrain, regions involved in memory formation and volitional behaviour and implicated in several neuropathologies. Our biochemical and behavioural experiments show that ATAC enables selective neuromodulation of these parts of the brain and that inhibitory ATAC is able to reduce traumatic memory formation in a model of contextual fear learning.
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on the hippocampus of wild-type mice. The hippocampus is implicated in a number of neurological and psychiatric disorders such as anxiety, epilepsy and Alzheimer's disease 36 . To achieve expression throughout this brain structure, we performed FUS-BBBO at six locations covering the ventral and dorsal hippocampus using an FUS instrument operating at 1.5 MHz guided by magnetic resonance The ATAC paradigm provides a combination of millimetre-precision spatial targeting using FUS, cellular specificity using viral vectors with cell-type-specific promoters driving the expression of chemogenetic receptors, and temporal control through administration of the chemogenetic ligand. b, In the ATAC sequence, the blood-brain barrier (BBB) is opened locally using FUS, and systemically injected AAV encoding a DREADD enters the treated area. After several weeks, the DREADD is expressed in the targeted region in cells possessing selected promoter activity. At any desired subsequent time, the DREADD-expressing neurons can be excited or inhibited through a chemogenetic drug such as CNO. Articles NaTurE BIomEdIcal ENGINEErING imaging (MRI) (Fig. 2a) . FUS was applied immediately after an intravenous (i.v.) injection of microbubbles and viral vector, with a gadolinium contrast agent coadministered to visualize regions with successful BBBO (Fig. 2b ). As our viral vector, we chose AAV9, a serotype of AAV with favourable tropism for neurons and large spatial spread after direct intracranial delivery 37 . This vector encoded the inhibitory DREADD receptor hM4Di, fused to the fluorescent reporter mCherry to facilitate histological visualization. This gene was encoded downstream of a calcium/calmodulin-dependent protein kinase II alpha (CaMKIIa) promoter, which was used to target ATAC specifically to excitatory neurons 38 . After allowing 6-8 weeks for transgene expression, the targeted locations showed widespread hM4Di expression in histological sections, covering most hippocampal regions and a small segment of cortex above the dorsal hippocampus (Fig. 2c) . Expression was especially strong in the molecular and polymorph layers of dentate gyrus, the stratum oriens and stratum radiatum of the CA1, CA2 and CA3 fields, as well as the pyramidal cells of the dentate gyrus, CA2 and CA3 (Fig. 2d) . Expression was present broadly throughout the hippocampus (Supplementary Fig. 1 ). By comparison, mice that received an i.v. injection of the same AAV9 vector without FUS-BBBO showed essentially no fluorescent signal in these brain regions (Fig. 2e) , confirming that BBBO was required for gene delivery at the viral dose used in this study. To assess the possibility of off-target expression in the peripheral nervous system, we performed immunostaining against hM4Di-mCherry in dorsal root ganglia (DRG). We found no expression of DREADDs in DRG ( Supplementary Fig. 2 ), consistent with another study showing poor efficiency of peripheral nerve transduction with AAV9 39 . A quantitative comparison of expression in FUS-targeted areas across five mice was performed using mCherry fluorescence in cell bodies of granular cell layers, which allowed for a direct comparison of transfection efficiency between hippocampal regions. Our analysis showed that more than 50% of the cells in dorsal and ventral CA3 and dorsal CA2 were successfully transfected, and that ventral and dorsal dentate gyrus contained 42% and 36% positive cell bodies, respectively (Fig. 3a,b) . The cortex and CA1 typically had lower transfection efficiencies, suggesting that these regions are less susceptible to transfection after BBBO than other hippocampal fields. As a representative non-targeted region, we looked for expression in the thalamus, which was shown in previous studies to be particularly susceptible to transfection following systemic delivery of AAV9 40 , and found no significant expression (< 5%, Fig. 3a,b) . Full results of the statistical tests can be found in Supplementary Table 1 . When compared with a direct intracranial injection of the same genetic construct using established protocols 41 , the percentage of mCherrypositive cell bodies at the sites of injection was similar to regions strongly expressing the construct after FUS-BBBO (52.8 ± 10.1%, n = 4 mice and eight injections analysed; Supplementary Fig. 3 ).
To evaluate the cellular specificity of genetic targeting, we compared expression of DREADDs in cells staining positively for CaMKIIa or glutamic acid decarboxylase (Gad) 1, which serve as labels of excitatory and inhibitory neurons, respectively (Fig. 3c,d ). We found that 98.4 ± 0.8% of the cells expressing the DREADD receptor also stained positively for CaMKIIa, while only 2.08 ± 2.08% of these cells co-stained for Gad1, confirming selective targeting of our constructs to excitatory neurons (n = 6, P = 4.75 × 10 , heteroscedastic two-tailed t-test; Fig. 3e ).
Targeted stimulation of the hippocampus. Depending on the DREADD encoded in the AAV vector, ATAC can be used to either stimulate or inhibit targeted neurons. To first assess the ability of , twotailed t-test assuming unequal variance; **P < 0.01. Bar graphs in a,e represent mean ± s.e.m.
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this technique to provide cell-specific activation, we targeted AAV9 carrying the excitatory DREADD hM3Dq fused to mCherry, under the CaMKIIa promoter, to the dorsal hippocampus using four FUS-BBBO sites. After allowing time for expression, we administered CNO i.p., and 2.5 h later perfused the mice to histologically monitor the expression of the activity-dependent gene product c-Fos in the dorsal CA3 region of the hippocampus (Fig. 4a) . We found that cells positive for hM3Dq expression were 5.8 times more likely to exhibit c-Fos staining than cells not expressing hM3Dq (Fig. 4b ,c, n = 6, P = 7.1 × 10
, two-tailed paired t-test), indicating that systemic chemogenetic treatment allows ATAC-targeted neurons to be selectively activated several weeks after the spatial targeting procedure.
Targeted inhibition of the hippocampus and effect on memory formation. To assess the ability of ATAC to inhibit targeted neurons, and to test the functionality of this technology in a behavioural paradigm, we used FUS-BBBO to target inhibitory DREADDs (hM4Di) to the ventral and dorsal hippocampus (Fig. 5a) , and assessed the impact of CNO administration on the formation of contextual fear memories. This well-established behavioural paradigm has been used in studies of anxiety, phobias, post-traumatic stress disorder and fear circuitry 42, 43 . Fear conditioning has also served as a testing ground for other neuromodulatory techniques 41, 44 . Since the hippocampus plays an essential role in memory formation, we hypothesized that inhibiting it non-invasively using the ATAC strategy would reduce the ability of mice to form fear memories.
Coverage of the hippocampus was achieved with FUS-BBBO applied to six sites ( Fig. 2) , accompanied by i.v. administration of AAV9 containing hM4Di-mCherry under the CaMKIIa promoter, to obtain ATAC mice. Two groups of control mice either were completely untreated or received i.v. virus without FUS-BBBO. After 6-8 weeks, the mice underwent a fear conditioning protocol (Fig. 5a ). In this protocol, the mice were placed in a unique environment (defined by chamber shape, lighting, smell and sound; context A in Fig. 5a ) while receiving three electric foot shocks, causing them to associate this environment with the noxious stimulus in a process known as contextual fear conditioning. Forty to sixty minutes before undergoing this protocol, each group of mice received injections of either CNO or saline to test the ability of targeted inhibition of ATAC-treated hippocampal neurons to reduce fear formation.
Twenty-four hours after conditioning, contextual fear recall was tested by placing mice in the same context and measuring freezing, an indication of fear 45 ( Fig. 5a ). ATAC mice treated with saline during conditioning froze 53.2% of the time, indicating robust fear recall. By contrast, ATAC mice that received CNO before conditioning froze only 21.8% of the time-a more than twofold reduction in fear memory (P = 1.9 × 10 −5
, n = 13 and n = 7, heteroscedastic twotailed t-test; Fig. 5b ). Comparing these two FUS-treated conditions allowed us to evaluate the efficacy of ATAC while accounting for any potential behavioural effects caused by the FUS treatment itself 46, 47 . Additional controls showed that the activation of any DREADDs potentially expressed outside FUS-targeted brain regions (after a systemic AAV9 injection, but in the absence of FUS-BBBO), or CNO treatment alone in wild-type mice, did not result in a reduction in contextual fear relative to untreated controls (Fig. 5c,d ). To confirm that the effect of activation of DREADDs was specific to fear formation and did not affect basic exploratory behaviour, we monitored treated and untreated mice in an open field test. One day after fear conditioning, the mice were placed in a novel environment (context B in Fig. 5a ), which they were allowed to explore freely for 3 min. The exploratory behaviour of all groups of mice was unaffected by CNO administration (Fig. 5e-g ).
To confirm that the effect of ATAC treatment was specific to inhibiting memory formation as opposed to sensation of stimuli such as pain, we paired each foot shock with an audible tone to produce an association between the tone and the shock in a process known as cued conditioning ( Supplementary Fig. 4a ). This process took place immediately during training and was not expected to be affected by inhibition of memory-forming regions of the hippocampus 41 . As expected, cued freezing measured at the end of the training session was unaffected by CNO treatment ( Supplementary  Fig. 4b-d) , indicating that ATAC-treated mice were not compromised in their ability to experience salient sensory stimuli.
Intersectional ATAC in transgenic animals. In addition to its potential therapeutic applications, ATAC may facilitate the study of neurological and psychiatric disease mechanisms in animal models by allowing the modulation of disease-related spatially defined neural circuits without surgery. A complementary resource for such studies is the large number of transgenic mouse and rat lines available with cell-type-specific expression of the Cre recombinase. The delivery of a viral vector encoding any gene of interest in a Credependent configuration allows the expression of this gene to be confined to the Cre-expressing cells in that animal 29 . To test whether ATAC could be used in combination with a Cre mouse line to provide non-invasive spatial and cell-type targeting of neuromodulation, we used FUS-BBBO to deliver a Cre-dependent DREADD construct into tyrosine hydroxylase / Cre (TH-Cre) transgenic mice 48 . These animals express the Cre recombinase in tyrosine-hydroxylasepositive dopaminergic neurons in the midbrain, especially in the substantia nigra pars compacta (SNc) and the ventral tegmental area (VTA). These regions are researched extensively in models of Parkinson's disease 49 , addiction and reward 50 and have previously been used to validate new neuromodulation techniques 51 . Due to , two-tailed t-test, assuming unequal variance, n = 6 independently targeted hemispheres in n = 3 mice; ***P < 0.001. Bars represent mean ± s.e.m. c, Representative immunohistology image of CA3 with c-Fos (yellow), hM3Dq-mCherry (red) and nucleus (TO-PRO-3; blue) staining. n = 6 independently targeted hemispheres analysed from n = 3 mice. Scale bar, 50 µ m.
Articles NaTurE BIomEdIcal ENGINEErING their locations deep within the brain and their small size, surgical access to these sites is difficult, and a non-invasive approach could reduce surgical damage along the needle tract while providing spatial selectivity.
To establish the feasibility of intersectional ATAC in a Cre mouse line, we used FUS-BBBO to spatially target a Cre-dependent 52 double-floxed inverted open reading frame (DIO) hM3Dq gene fused to mCherry, under the human Synapsin-1 promoter (DIOSyn1-hM3Dq-mCherry), encoded in AAV9 to the midbrain on a single side of the brain (Fig. 6a) , then tested our ability to activate TH-positive neurons in this region with CNO by imaging c-Fos accumulation (Fig. 6b) . FUS-BBBO applied to the midbrain resulted in a BBBO that partially overlapped with the expected location of the SNc/VTA (Fig. 6c) . Subsequent immunofluorescent imaging of brain sections revealed hM3Dq was present in the SNc/VTA at the FUS-BBBO site (Fig. 6d,e) and not at the contralateral site or in the DRG (Supplementary Fig. 5 ). We then tested the functionality of our DREADD receptor by staining for c-Fos-positive nuclei at the , two-tailed heteroscedastic t-test; ***P < 0.001). c, Percentage of time spent freezing in the fear recall context (context A) for mice that received i.v. injection of AAV-DREADD without FUS-BBBO, with CNO and saline treatment (no effect found, P = 0.69, two-tailed heteroscedastic t-test). d, Percentage of time spent freezing in the fear recall context (context A) for wild-type mice treated with CNO or saline (no effect found, P = 0.17, two-tailed heteroscedastic t-test). e, Exploratory activity score in the non-fear context (context B) for ATAC mice treated with CNO or saline (P = 0.81, two-tailed heteroscedastic t-test). f, Exploratory activity score in the non-fear context (context B) for mice that received i.v. injection of AAV-DREADD without FUS-BBBO, with CNO or saline treatment (no effect found, P = 0.65, two-tailed Mann-Whitney test used due to non-normal distribution of data points). g, Exploratory activity score in the non-fear context (context B) for wild-type mice that received CNO or saline treatment (no effect found, P = 0.79, two-tailed heteroscedastic t-test). All bar graphs represent mean ± s.e.m. The n values under each bar indicate the number of mice tested in that experimental condition. a.u., arbitrary units.
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NaTurE BIomEdIcal ENGINEErING site of FUS-BBBO and the contralateral region. Among TH-positive neurons, we found a 7.3-fold increase in activation on the side of the brain targeted by the ATAC treatment after CNO administration (Fig. 6f , n = 5 mice, P = 0.0011, paired two-tailed t-test). Since ligand-independent activity of DREADDs has recently been shown to be present in peripheral neurons 53 , we also tested c-Fos accumulation in the absence of CNO to evaluate this possibility in our experiments. We found no activation after saline administration ( Supplementary Fig. 6 , n = 4, P = 0.26, paired two-tailed t-test).
These results demonstrate spatially selective, CNO-dependent, intersectional neuromodulation in a Cre mouse line.
Tolerability of ATAC by brain tissue. Finally, to confirm that ATAC treatment is well tolerated by brain tissue, we examined hematoxylin-stained brain sections from 14 mice with a total of 84 FUS-BBBO sites. Consistent with previous findings 54 , the majority of these sites (71.4%) had normal histology ( Supplementary  Fig. 7a,b) . In the remaining FUS-targeted sites, we found small areas of apparent tissue damage with mean dimensions of 115 µ m × 265 µ m, which were not visible on sections ± 300 µ m away from the site (Supplementary Fig. 7b,c) . The average calculated volume of these features was 0.0027 ± 0.0007 mm 3 . This represents less than 0.1% of the typical FUS-BBBO site, which has a volume of 2.81 ± 0.51 mm 3 (average of n = 7 sites quantified by MRI), and 0.01% of the mouse hippocampus (volume of 26 mm 3 ) 55 . By comparison, the volume of brain displaced during invasive viral injections using typical needle gauges (27) (28) (29) (30) (31) (32) (33) Supplementary Fig. 7d ), resulting in damage still present seven weeks after the injection (Supplementary Fig. 7e ). These results are consistent with the normal performance of ATAC-treated mice in behavioural tests and the ability of ATACtreated regions to become chemogenetically activated and express c-Fos. In future translational studies, this safety profile could be further improved with feedback-controlled FUS-BBBO 56 .
Discussion
Taken together, our results establish ATAC as a paradigm for noninvasive neuromodulation with a unique combination of spatial, cell-type and temporal specificity. This paradigm holds several advantages over existing techniques for both research and potential clinical applications. Compared with intracranial injections for viral gene delivery, which are invasive and often require multiple brain penetrations to cover the desired area (up to dozens in larger species 57, 58 ), FUS-BBBO enables comprehensive transduction of an entire brain region in a single session with relatively minimal tissue disruption and can more easily be scaled to larger animals and humans. Unlike optogenetics or electrical stimulators, ATAC can achieve neuromodulation non-invasively, without the need for permanently attached or implanted devices for chronic use. Since AAVs are being investigated in clinical trials with promising results [24] [25] [26] 56 , and FUS-BBBO has also been tested in the clinic 10 , ATAC could become clinically relevant. While recent developments in AAV vectors also enable some variants to cross the BBB on their own 40 , they do so without spatial selectivity.
Compared with emerging ultrasonic neuromodulation techniques in which ultrasound directly activates or inhibits brain regions or locally delivers neuromodulatory compounds 60-68 , ATAC does not require an ultrasound transducer to be mounted on the subject during modulation. After transduction and expression of chemogenetic receptors in a genetically defined subset of cells at the FUS-targeted site, neuromodulation is conveniently controlled using a systemically bioavailable drug. The fact that a single FUS-BBBO session is required should also minimize the potential for non-specific cellular-level effects after multiple FUS-BBBO treatments 69, 70 . In our behavioural proof of concept, a single injection of CNO several weeks after the FUS-BBBO procedure resulted in a 2.4-fold reduction in fear memory formation without any effects on normal exploratory behaviour. In addition, both the cell types modulated in the chosen brain region and the polarity of the modulation can be chosen precisely using cell-type-specific promoters and excitatory or inhibitory receptors. Finally, we showed that ATAC is compatible with intersectional genetic targeting in transgenic animals, making it potentially useful in a wide variety of basic and disease model studies. , paired two-tailed t-test, n = 5 mice; **P < 0.01; bars represent mean ± s.e.m), together with representative histology images of the targeted and contralateral brain regions stained for c-Fos (yellow), TH (blue) and hM3Dq-mCherry (red). Scale bars, 100 µ m.
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The ATAC paradigm could be made more powerful with improvements in each of its components: FUS-BBBO, AAV vectors, cell type-specific promoters, chemogenetic receptors and ligands. For example, the incidence of FUS-induced lesions can be reduced through real-time monitoring of bubble cavitation to maximize molecular delivery while minimizing the possibility of damage 56, [71] [72] [73] . The use of phased array transducers and protocols correcting skull-induced aberrations in the ultrasound field 20, [74] [75] [76] [77] could facilitate the scaling of ATAC to larger animals. At the same time, larger ultrasound transducer apertures (lower f-numbers) could reduce the focal zone size to make targeting more precise, while pulse sequences using chirps and random-based coded ultrasonic excitation 78 could reduce reverberations 79, 80 within the brains of smaller animals. Finally, in research applications, FUS devices that perform targeting on the basis of stereotaxic coordinates rather than MRI guidance should make ATAC accessible to a broader range of neuroscience laboratories.
Additional work is also needed to make AAV vectors more efficient to reduce their required dose, and to make compact celltype-specific promoters that work robustly in primates 28 . Finally, there are ongoing studies of the pharmacokinetics of chemogenetic ligands and receptors. It has recently been shown that CNO is metabolized to clozapine, which then activates DREADDs with high affinity 81 . Such studies highlight the need for continued optimization of ligands and their dosing for DREADD activation, and motivate the use of alternative ligands 82 and chemogenetic receptors 83, 84 , especially in species where metabolism of CNO to clozapine is significant. These improvements will facilitate the development and translation of ATAC as a paradigm for precise non-invasive control of neural circuits.
Methods
Animals. C57BL/6J mice were obtained from Jackson Lab. Transgenic THCre mice were obtained from an internal colony at the California Institute of Technology and were originally generated 48 at Uppsala University. Animals were housed in a 12 h light/dark cycle and were provided with water and food ad libitum. All experiments were conducted under a protocol approved by the Institutional Animal Care and Use Committee of the California Institute of Technology.
FUS-BBBO.
Male, 13-18-week-old C57BL/6J mice were anaesthetized with 2% isoflurane in air, the hair on their head removed with Nair depilation cream and then cannulated in the tail vein using a 30 gauge needle connected to PE10 tubing. The cannula was then flushed with 10 units (U) ml −1 of heparin in sterile saline (0.9% NaCl) and affixed to the mouse tail using tissue glue. Subsequently, the mice were placed in the custom-made plastic head mount and imaged in a 7 T MRI (Bruke Biospec). A fast low-angle shot sequence (echo time TE = 3.9 ms, repetition time TR = 15 ms, flip angle 20°) was used to record the position of the ultrasound transducer in relation to the mouse brain. Subsequently, the mice were injected via tail vein with AAV9 (1 × 10 10 viral particles per g) encoding DREADDs in plasmids containing inverted terminal repeats of AAV (pAAV): pAAV-CaMKIIa-hM4Di-mCherry (Addgene plasmid no. 50477) or pAAV-CaMKIIa-hM3Dq-mCherry (Addgene plasmid no. 50476), both plasmids a gift from B. Roth (University of North Carolina). Immediately after viral injection, the mice were also injected with approximately 1.5 × 10 6 DEFINITY microbubbles (Lantheus) and 0.125 µ mol of ProHance (Bracco Imaging) dissolved in sterile saline, per g of body weight. The dose of DEFINITY was optimized through preliminary studies from a starting point obtained from the literature 85 . The dose of ProHance was chosen on the basis of the manufacturer's recommendations. Within 30 s, the mice were insonated using an eight-channel FUS system (Image Guided Therapy) driving an eight-element annular array transducer with a diameter of 25 mm and a natural focal point of 20 mm, coupled to the head via Aquasonic gel. Gel was placed on the top and both sides of the animal's head to minimize reverberations from tissue/air interfaces. The focal distance was adjusted electronically, as shown in Supplementary Fig. 8 , to target specific brain regions. The ultrasound parameters used were 1.5 MHz, 1% duty cycle and 1 Hz pulse repetition frequency for 120 pulses and were derived from a published protocol 17 . The pressure was calibrated using a fibre optic hydrophone (Precision Acoustics), with 21 measurements and an uncertainty of ± 3.8% (s.e.m.). The pressure for FUS-BBBO was chosen on the basis of multiple studies 17, 86 and preliminary experiments in our lab. The ultrasound parameters were 1.5 MHz, 0.42 MPa pressure accounting for skull attenuation (18%) 23 , 1% duty cycle and 1 Hz pulse repetition frequency for 120 pulses. For each FUS site, DEFINITY and ProHance were re-injected before insonation. After FUS-BBBO, the mice were imaged again using the same fast low-angle shot sequence to confirm opening of the BBB and appropriate targeting. Immediately afterwards, the mice were placed in the home cage for recovery. The TH-Cre animals, all aged 18 weeks, were subjected to FUS-BBBO using the same protocol and using the same dose of AAV9 as for the C57BL/6J mice. All the THCre animals were females.
MRI images were analysed using the ImageJ 'measurement' function. To estimate the size of the BBBO, we used a single FUS beam using standard parameters. The hyperintense area from ProHance extravasation was delineated manually, and the dimensions of the minor and major axes were recorded for n = 7 animals. The volumes were calculated assuming an ellipsoid shape. For the MRI intensity calculation, the four sites of FUS-BBBO in the dorsal hippocampus were delineated manually, and average signal intensity was calculated within the region for each mouse. The result was then divided by a mean signal intensity in an untargeted thalamus 1.5-2 mm below the hippocampus. The result was then compared with the size of an ultrasound beam.
Intracranial injection. Solutions of AAV9 encoding hM4Di-mCherry under a CaMKIIa promoter were injected into the hippocampus of male C57BL/6J mice (Jackson Lab) at 18 weeks of age using a NanoFil blunt-end 33 g needle coupled with a motorized pump (World Precision Instruments) at 100 nl min −1 using a stereotaxic frame (Kopf). The coordinates of the two pairs of sites with respect to the bregma were − 2.2 mm anterior-posterior, ± 2 mm medio-lateral, − 1.7 mm dorso-ventral and − 3.2 mm anterior-posterior, ± 3.5 mm medio-lateral and − 3 mm dorso-ventral. The needles remained in place after injection for 5 min to avoid backflow along the needle tract. The total volume of injection used was 500 nl. The total viral load was 5 × 10 8 in 0.5 µ l per site, following previously published dosing 41 , and seven weeks was allowed for expression to match the timeline used for analysis of expression and damage following FUS-BBBO.
c-Fos activation and immunostaining. C57BL/6J male mice of 13 weeks of age underwent FUS-BBBO to administer AAV9 carrying hM3Dq-mCherry into the hippocampus. Subsequently, the mice were housed singly to reduce background c-Fos expression. After 22 weeks of expression, the mice received an i.p. injection of 1 mg per kg CNO in sterile saline and were returned to the home cages. After 150 min, the mice were anaesthetized using ketamine/xylazine solution (80 mg per kg and 10 mg per kg, respectively, in PBS buffer) and perfused with cold PBS/heparin (10 U ml ), and immediately afterwards with 10% neutral buffered formalin. Their brains were extracted and postfixed in 10% neutral buffered formalin for at least 24 h. Brain sections (50 µ m) were obtained using a VF-300 Compresstome (Precisionary Instruments). Subsequently, sections were blocked in 10% normal donkey serum and 0.2% Triton-X solution in PBS for 1 h at room temperature, and immunostaining with the primary antibody was performed using a goat anti-c-Fos antibody (SC-253-G, Santa Cruz Biotechnology) in 10% normal donkey serum and 0.2% Triton-X overnight at 4 °C. Afterwards, the sections were washed three times in PBS and incubated with a secondary donkey anti-goat antibody conjugated to Alexa Fluor 488 (A-11055, ThermoFisher). For activation of the hippocampus, the histological evaluation was performed by an observer blinded to the identity (hM3Dq positive or negative) of granular-layer nuclei in dorsal CA3. The expression status of the neurons was determined after the scoring of c-Fos positivity. The cells were counterstained using TO-PRO-3 (ThermoFisher). The activation of TH neurons was evaluated by an observer blinded to the presence of FUS-BBBO targeting at a given site. TH-Cre mice expressed hM3Dq for nine weeks after FUS-BBBO, and were then given 1 mg per kg CNO. After 2 h, they were anaesthetized with ketamine/xylazine (80/10 mg per kg in PBS) and perfused using cold PBS/heparin (10 U ml ) and then 10% neutral buffered formalin. At least two sections per animal were used for c-Fos immunostaining of hM3Dq activation experiments, and all of the pyramidal neurons (for hippocampus experiments) or TH cells (for intersectional ATAC experiments) within each section were used for analysis. The saline control of c-Fos activation experiments in intersectional ATAC used one section per mouse, and all TH cells within each section were used for analysis. A three-dimensional reference atlas 87 was used to choose the appropriate regions and brain sections for each mouse and contralateral and ipsilateral controls to ascertain consistency in the choice of analysed sections. One region of interest in one out of six TH-Cre mice was damaged during sectioning, and the mouse could not be included in c-Fos evaluation. The time points for c-Fos testing were chosen on the basis of previous literature 88, 89 .
Gene expression evaluation. The gene expression timeline was chosen on the basis of previous studies indicating that the expression of genes delivered with AAV9 is stable after six weeks 90 and showing activity of DREADDs after that time point 91, 92 . In addition, the long-term expression of 22 weeks in Fig. 4 was chosen to establish whether DREADDs remain active after a longer period of time following FUS-BBBO delivery. To visualize DREADD expression across brain regions, we used immunostaining with a polyclonal rabbit anti-mCherry antibody (PA534974, ThermoFisher), a polyclonal goat anti-CaMKIIa antibody (PA519128, ThermoFisher) and a polyclonal goat anti-Gad67 (103220-296, LifeSpan) antibody in 10% normal donkey serum (D9663-10ML, Sigma-Aldrich) and 0.2% Triton-X in Articles NaTurE BIomEdIcal ENGINEErING PBS overnight at 4 °C. The TH expression was evaluated using an anti-TH chicken antibody (TYH, Aves Labs) incubated in normal goat serum (NS02L-1ML, SigmaAldrich) and 0.2% Triton-X in PBS overnight at 4 °C. The expression of protein gene product (PGP) 9.5 was evaluated using rabbit anti-PGP9.5 (ab10404, Abcam), incubated in 0.2% Triton-X in PBS overnight at 4 °C. Secondary antibodies were donkey anti-rabbit conjugated to DyLight 650 (84546, ThermoFisher), donkey anti-goat conjugated to DyLight 488 (SA5-10086, ThermoFisher) and goat antichicken conjugated to Alexa Fluor 488 (A-11039, ThermoFisher). Secondary antibodies were incubated in 10% normal donkey serum / 0.2% Triton-X in PBS for 4 h at room temperature. For quantitative comparison of expression levels between various regions of the hippocampus, we used mCherry fluorescence localized to cytoplasmic compartments and counted the number of cells in the pyramidal layers of the hippocampus showing detectable fluorescence. Cells were co-stained with a nuclear stain (4,6-diamidino-2-phenylindole (DAPI)) to allow delineation of nuclei and surrounding cytoplasmic regions. Cells that showed mCherry fluorescence surrounding the nucleus for at least 50% of its circumference were counted as positive to allow for a consistent comparison of expression between different hippocampal regions and conditions. The non-cytoplasmic localization of DREADD-mCherry necessitated the selection of this threshold. All the images were background normalized to allow for comparable evaluation of expression. Sections were obtained at 50 µ m serially, in order. All sections were inspected for expression at a low-power fluorescent microscope, and representative sections were then imaged on a confocal microscope. Expression was evaluated for 3-5 sections per animal, and cells from each subfield of the hippocampus were added for each animal and normalized by the number of DAPI stained cells in the granular cell layer of that subfield. The interexperimenter variability was determined for two different researchers (B.L., J.O.S.) for n = 6 samples, with the difference in means smaller than 2.5% (mean = 42.5% versus mean = 41.5%, P = 0.92, heteroscedastic two-tailed t-test).
Behavioural testing. Behavioural studies for fear conditioning were performed in sound-attenuated fear conditioning chambers (30 cm × 25 cm × 25 cm, Med Associates). Animals were trained and tested for contextual fear in context A, which comprised a staggered wire grid floor, white light, 5% acetic acid for scent and no background noise. Locomotor testing was performed in context B, which was differentiated from context A by chamber shape, floor, illumination, odour, background noise and room location. Animal activity was recorded and quantified using Video Freeze software (Med Associates). For cued training, the tone was 80 dB and 30 s.
Fear conditioning. Mice were injected with CNO (10 mg per kg, i.p.) or equivalent volume of saline (i.p.) and, after 40-60 min, underwent contextual and cued fear conditioning in context A. This timeframe was chosen to allow CNO to reach its pharmacokinetic peak 93 . An initial baseline period of 3 min was followed by 3 × 30 s presentations of a tone co-terminated with a 2 s foot shock (0.7 mA), with an intertrial interval of 60 s. After the trials, the mice remained in the context for an additional 60 s, after which they were transported back into the vivarium. After 24 h, the mice were placed in context A to record contextual fear for the duration of the training (8 min and 40 s).
Exploratory behaviour analysis. Between 30 min and 45 min after the contextual fear test, the mice were transported to another room, placed in context B and allowed to explore the chamber for 3 min while their activity was recorded. Due to automated data acquisition and evaluation, no blinding was necessary.
Fear conditioning analysis. The mice were recorded using automated near-infrared video tracking in the fear conditioning chamber using the Video Freeze software. Mouse motion was measured using the activity score, from a video recording at 30 frames per second, with the motion threshold set at 18 activity units (the standard value in the software). Freezing was defined as an activity score below 18 units for at least 1 s. Average freezing in the context test was scored over the whole trial. Due to automated data acquisition and evaluation, no blinding was necessary.
Exclusions. Mice were excluded from the statistical analysis if their histologically determined DREADD expression was below 30% of cell bodies in the dorsal CA3 region of the hippocampus. This threshold was chosen on the basis of previous studies showing that behavioural effects generally require modulation of at least 30% of the neurons in a targeted region 94, 95 , and dorsal CA3 being the most robustly transfected hippocampus region. The resulting analysed groups had identical levels of expression (55.1% for the saline group and 60.5% for the CNO group, P = 0.26, heteroscedastic two-tailed t-test). In analyses including all mice, we found that DREADD expression in dorsal CA3 correlated with the formation of contextual fear memories in mice treated with CNO (coefficient of correlation r = 0.62, n = 11), but not in mice receiving saline (r = 0.14, n = 14) ( Supplementary  Fig. 9a ). Even without excluding the four mice that had expression below 30%, a direct comparison between ATAC mice treated with CNO and saline showed a statistically significant reduction of contextual fear (53.2% versus 34%, n = 13 and n = 11, P = 0.0193, heteroscedastic two-tailed t-test). Variability in gene expression may have been due to variability in i.v. injections of virus during the FUS-BBBO procedure, since we found no difference between these mice in longitudinal relaxation time (T 1 )-weighted MRI signal enhancement post-FUS-BBBO (Supplementary Fig. 9b ).
Statistical analysis. Data were analysed using either a two-tailed t-test with unequal variance (when two samples were compared and when data were deemed normal with a Shapiro-Wilk test) or one-way analysis of variance with a Tukey honestly significant difference post hoc test (when more than two samples were compared). All data with P < 0.05 were considered to be significant. All data were tested for normality using a Shapiro-Wilk test. Samples with two conditions and non-normal distributions were tested by a nonparametric test (Mann-Whitney). All central tendencies reported are averages.
Histological analysis. Analysis of the FUS-BBBO safety was performed using hematoxylin staining and autofluorescence. All of the vibratome sections (50 µ m) within the hippocampus were imaged under a microscope with a × 10 objective to identify potential lesions (n = 14 mice). The sections showing the largest anomalies were then observed at a greater magnification (× 20 objective). The FUS-induced lesions were autofluorescent, and fluorescence microscopy was used for measurements. The volumes were calculated assuming an ellipsoid shape of the damage, with maximum diameters within a section used for the major and minor axes. The volume of lesions was calculated using an ellipsoid volume formula (volume v = 4/3 × π × (width/2) 2 × length/2). To confirm the anatomy of the lesions, hematoxylin staining was performed: vibratome sections were stained for 30-45 s in 20% Gill no. 3 hematoxylin, followed by a brief wash in PBS and a 5 s dip in Rapid-Chrome blueing solution (ThermoFisher). Each section was then washed twice in PBS and mounted in a water-based medium (ProLong Gold, ThermoFisher).
Illustrations. The structure of AAV9 96 in Fig. 1 was rendered using QuteMol 97 . The three-dimensional rendering of the hippocampus in Fig. 2 was generated using the Rhinoceros software with models obtained from a three-dimensional brain atlas reconstructor 98 and a Waxholm space dataset 99 .
Reporting Summary. Further information on experimental design is available in the Nature Research Reporting Summary linked to this article.
Data availability.
The authors declare that all data supporting the findings of this study are available within the paper and its supplementary information. Raw data files are available from the corresponding author upon reasonable request. 
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Data collection
We used Video Freeze v2.0 (Med Associates) for video capture and behavioral analysis. We used ThermoGuide v3846 (Image Guided Therapy) and Paravision v5.1 (Bruker) for MRI-guided focused ultrasound and MRI image acquisition.
Data analysis
We used Excel 2013 (Microsoft), Prism v7 (Graphpad), ImageJ v1.50a (NIH) and Zen v2. For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.
